Adaptimmune Quarterly report pursuant to Section 13 or 15(d)

Marketable securities - available-for-sale debt securities (Tables)

Marketable securities - available-for-sale debt securities (Tables)

9 Months Ended

Sep. 30, 2022

Marketable securities - available-for-sale debt securities

As of September 30, 2022, the Company has the following investments in marketable securities (in thousands):


				Gross		Gross		Aggregate
	Remaining	Amortized		unrealized		unrealized		estimated
	contractual maturity	cost		gains		losses		fair value
Available-for-sale debt securities:
Corporate debt securities	Less than 3 months	$	12,410	$	—	$	(43)	$	12,367
U.S. Treasury securities	Less than 3 months		18,117		—		(51)		18,066
Agency bonds	3 months to 1 year		5,000		—		(168)		4,832
Corporate debt securities	3 months to 1 year		84,319		—		(1,277)		83,042
Corporate debt securities	1 year to 2 years		2,447		—		(85)		2,362
		$	122,293	$	—	$	(1,624)	$	120,669

Schedule of aggregate fair value and number of securities held by the Company in an unrealized loss position

The aggregate fair value (in thousands) and number of securities held by the Company (including those classified as cash equivalents) in an unrealized loss position as of September 30, 2022 and December 31, 2021 are as follows:


	September 30, 2022						December 31, 2021
	Fair market value of investments in an unrealized loss position		Number of investments in an unrealized loss position		Unrealized losses		Fair market value of investments in an unrealized loss position		Number of investments in an unrealized loss position		Unrealized losses
Marketable securities in a continuous loss position for 12 months or longer:
Corporate debt securities	$	34,519		6	$	(393)	$	8,232		1		(35)

Marketable securities in a continuous loss position for less than 12 months:
Corporate debt securities	$	63,252		14	$	(1,012)	$	163,258		34	$	(348)
U.S. Treasury securities		18,066		3		(51)		—		—		—
Agency bond		4,832		1		(168)		4,993		1		(7)
	$	120,669		24	$	(1,624)	$	176,483		36	$	(390)